

2023 Financial Reports



We're stronger **together**

Directors' Report

The Directors of the Company, Muscular Dystrophy Queensland Limited (MDQ) present their report for the period 1 January to 31 December 2023. This report is to be read in conjunction with Muscular Dystrophy Queensland's Financial Statements and Annual Report for the same period.

Objectives were set within the context of continual and significant financial challenges, caused by the following external factors:

- I. Managing a business subject to the National Disability Insurance Scheme (NDIS) quality indicators and practice standards.
- II. Inability to raise prices across most service provision due to frozen price caps across all services; since 1 December 2018 for therapy services and 1 December 2019 for NDIS intermediary services.
- III. Sharp rises in operating costs due to high inflation, with most suppliers raising the prices at some point during the year.
- IV. Difficulty attracting and retaining quality staff, due to thin labour markets.

1. Strategic Objectives

These are outlined in the Muscular Dystrophy Queensland Ltd Strategic Plan 2022-2025 and are as follows:

Long-term objectives

- I. Build our community by extending our reach and the richness of our engagement throughout Queensland and building social connection amongst community members.
- II. Deliver services of superior quality and value for our clients, continually growing and diversifying services.
- III. Provide donors and supporters with fundraising programs which offer the greatest opportunities for them to invest in the work of Muscular Dystrophy Queensland.
- IV. Grow, develop and empower our workforce through continual improvement, flexible conditions which attract and retain great people who contribute to a culture of commitment and loyalty to the organisation, and mutual respect for each other.
- V. Strive for organisational excellence; prioritising financial stability, environmental sustainability, continual improvement in governance, risk management and across all operational business units.

Objectives for 2023

- I. Relocate to suitable, affordable premises which meet the accessibility requirements of our community members.
- I. Review business needs to reduce operating expenses and attain financial stability.
- II. Manage growth in client services prioritising;
 - building the number of community members,
 - increasing revenue in NDIS-aligned services,
 - responding to requests for support via charitable programs, and
 - renewing social and community connection programs, responding to client feedback.
- III. Grow surpluses in fundraising programs with careful investment.
- IV. Maintain a leadership role in Muscular Dystrophy Foundation Australia
- V. Where possible, continue progressing long-term objectives as outlined in the Strategic Plan: 2022 – 2025.

2. Principal Activities

Muscular Dystrophy Queensland (MDQ) is a state-wide organisation, providing whole-of-life services and systemic advocacy for Queenslanders living with muscular dystrophy and similar conditions and their families. To achieve our mission of empowering our community members to make the most of opportunities and live the lives they choose, we undertake the following activities:

- Charitable services which address challenges commonly experienced by our community members.
- User pays services which address expressed community needs and are aligned to the NDIS funding framework but can also be accessed via health insurance, private funds, aged care plans etc.
- Fundraising activities, including donation appeals, fundraising events and lotteries.

Charitable services include:

- I. Infoline & Information Resources: Individualised support for callers, information resources via Muscular Dystrophy Queensland's website, social media and a periodical for community members.
- II. NDIS Access: Supporting community members to access lifetime funding through eligibility application for an NDIS Plan.
- III. Equipment Loans: Short term cough assist machine loans for anyone experiencing an acute respiratory infection, long-term loans of hi-lo beds and mobility equipment for people without government funding.
- IV. Extended Care: Case management to assist community members overcome a challenge related to living with a muscle wasting condition.
- V. Outreach: Funding travel and accommodation costs to periodically deliver services into regional and remote centres.

- VI. Community Connection: Providing in-person and online events for community members to meet and form friendships.
- VII. Systemic Advocacy: Seeking positive change; addressing the challenges commonly experienced by our community members.

User pays services include

- I. Allied Health Services
 - Physiotherapy
 - Occupational therapy
 - Allied health assistance
- II. NDIS Intermediary Services
 - Support coordination and specialist support coordination
 - Plan Management

Fundraising portfolio includes

- I. Donation appeals and stewardship of donors
- II. Regular lotteries and auto-giving club membership
- III. Events hosted in partnership with our supporters
- IV. Applications for program funding via charitable trusts and foundations grant funding

3. Key Performance Measures

The company measures its performance through both quantitative and qualitative benchmarks, used by Directors, CEO and senior staff to assess the success and sustainability of Muscular Dystrophy Queensland.

Quantitative

Key Performance Indicator (KPI)	Performance against KPI
Community: 5% growth in number of community members	5.7% growth achieved. Entries in 3023 = 72. Sadly, there were 19 client deaths during 2023. Another 15 people were exited due to loss of contact.
Operations: Achieve 2023 budget (reducing business expenses to reduce initially predicted deficit).	The deficit at 31 Dec 2023 of \$41,667 was more than \$200,000 smaller than initial budget forecast.
Operations: Maintain staff turnover of <25%	5 of 20 staff employed in January 2023 were no longer working for MDQ by December 2023, being a 25% turnover; 1 management, 1 admin, 3 allied health.
NDIS Services: Teams achieve billable hours targets; Allied health 65%; Support Coordination 70%	Allied health team achieved 54%, impacted by staff turnover including the loss of the fulltime OT position in July 2023. Support Coordination achieved 63% billable hours slightly below KPI due to staffing transitions/onboarding.
Government Funding Programs: Achieve contracted performance indicators in Community Self Care and Specialist Disability Supports in Schools (SDSS) programs. Secure additional government grant funding.	Program deliverables were achieved with acquittal reports submitted by Q1 2024. Despite our efforts appealing to local, state and federal government representatives, we did not secure additional program funding from government grants.
Fundraising: Achieve budgeted revenue and reduce expenditure, resulting in higher a program surplus than prior year.	All fundraising programs raised greater revenue than budgets other than events, which predicted higher revenue from the RWSP Ball. Overall program surplus increased by 13.5% on prior year.

Qualitative

Key Performance Indicator (KPI)	Performance against KPI
Compliance & Quality: Successfully undergo external financial audit and continue development of business processes in line with NDIS practice standards and quality indicators.	Completed with 0 business improvement recommendations, 5 matters raised as a low risk rating, 2 as a moderate risk rating, 0 as high risk. Management agreed with moderate risks and had taken steps to address them.
Community Inclusion: Embed processes for feedback from Client Liaison Group to influence strategy and operations.	CLG Chair appointed. Regular CLG meetings attended by GM - Community Services. Formal feedback to the board via CEO Reports, attends meetings.

Key Performance Indicator (KPI)	Performance against KPI
Continuous improvement: Streamline operational processes and document work instructions across all business units.	HR: HRIS transition project funding secured. Project initiated and on track for completion June 2024. Fundraising Team: Fundraising work instructions updated to include new events and processes related to Vega CRM. Client Services Admin: Move to Echidna CRM, related work instructions updated.
Governance: Ensure Directors are informed to provide strategy and direction during challenging circumstances.	Achieved through increased board meetings and oversight by Finance & Risk Committee. Restructured Board Report Pack to improve clarity.
Finance: Ensure financial agility to respond to challenging circumstances.	Achieved through maintaining highly liquid financial assets in interest-bearing term deposits. Replaced exiting finance staff with contractor for payroll & external CFO.
Operations: Finalise hybrid work model, reduce size and cost of leased premises by end 2023.	Achieved. Office relocated to Underwood in October 2023.
Staff satisfaction: Increase staff satisfaction and engagement.	Achieved. In early 2023 staff reported dissatisfaction with the temporary office arrangements, 2 cited poor office atmosphere as their reason for leaving. By end 2023, the majority of staff reported high satisfaction with the new premises & IT support to successfully work remotely.

4. Review of operations

Muscular Dystrophy Queensland is a niche provider, dedicated to the neuromuscular community who form a small percentage of the broad market of people with disability. As a member-based organisation, dedicated to meeting the needs of our community we sought feedback on the model of services which our community expected from MDQ. Resoundingly they told us, they wanted MDQ to retain its specialist focus on meeting the needs of people living with neuromuscular conditions.

The pricing structure of the NDIS is not sufficient to meet the costs of providing services for our cohort, which requires a more expensive model of care, delivered in community and in clients homes, spread across the South East Corner and further into the State via outreach, by highly-qualified professionals.

2023 was a third, financially challenging year, where the board and management prioritised financial management, and made difficult decisions, aiming to reduce expenses, source additional income and improve financial sustainability.

Management restructure

Upon the retirement of former CEO, Helene Frayne, there was an opportunity to restructure staffing and for another successive year, reduce staffing to save costs. Penny Deavin stepping up to the role provided stability and retained her finance, operations and fundraising expertise. The role of GM - Business & Development was deleted and Penelope Hodge was appointed to the newly created position; GM - Community Services. By the end of 2023, most middle management positions had been deleted in favour of the more cost-efficient, flat organisational structure.

Legacy of pandemics and extreme weather events

The positive long-term legacy of COVID has been its impact on the way we work. Staff were now successfully working under a hybrid arrangement. With our leases expiring and the urgent need to cut operating costs we initially considered transferring to an entirely virtual work model. However, the feedback from staff, our community and other external stakeholders was resounding. They appreciated MDQ having a footprint. Review of available commercial real-estate provided a clear illustration of the impact of 2022's floods on Brisbane's inner northside. So many local business had been forced to move from flood affected buildings, pushing leasing costs in the area to disproportionately high rates. It was no longer an affordable base.

Relocation

We applied, unsuccessfully to take up peppercorn leases with Queensland Health Departments, with Brisbane, Logan and Ipswich City Councils and other Queensland Government departments. We approached like-minded community based organisations, which might also have surplus office space, suitable for co-locating. There was interest but no urgency to the negotiations and it was necessary for MDQ to find a solution. In the end, stand-alone leased premises were available in Underwood at 50% less than previous 1149 Sandgate Rd property. The board agreed to a 2 year lease beginning October 2023, enabling the Directors the opportunity to reassess the suitability of the location in late 2025.

Client services

Throughout this difficult year, Muscular Dystrophy Queensland's team strove to meet community demand for services. Responding to feedback in the 2022 Client Survey, we prioritised the re-introduction of community connection and information events to provide opportunities for community members to meet, form friendships and share experiences. With the support of our donors and charitable foundations, MDQ provided free school holiday events for children, the first of many information and connection

events (this one for members living with Myotonic MD) and our Brisbane Christmas Party. Allied Health Services struggled to provide stability due to staff turnover. The loss of popular occupational therapist, Emma Larwill, in July was a blow to the developing service and was not quickly filled, due to the ongoing challenge of thin employment markets.

Fundraising

The fundraising team, led by Fundraising & Marketing Manager, Bruce Nean, performed admirably exceeding revenue budget across almost every program and conservatively managing expenditure to bring costs in below expectations. With most areas performing stably, the team focused on modernising the lotteries program but faced bottlenecks due to our CRM provider delaying release of a promised lottery management module. Digital technologies were also relied on to streamline fundraising in the Ride, Wall, Roll and Red Bow Day, improving the donor experience.

Conclusion

Financial management will continue to be challenging until the NDIS raises its prices in line with the true costs of providing a quality service or the organisation is able to secure recurrent government grant funding and increase surpluses from fundraising. Despite all of these challenges, we are committed to enabling our members to live the lives they choose.

5. Director Attendance at Meetings

In 2023, three additional board meetings were held making a total of eleven board meetings. Directors commonly chose online attendance at these meetings.

Director	Position Title	Board Meetings		Risk & Finance (R&F) Committee Meetings	
		Eligible to Attend	Attended	Eligible to Attend	Attended
Mr. Victor Attwood	Chair	8	8	3	3
Mr. Anthony Biggar	Director	8	7	-	-
Dr. Cullen O’Gorman	Director	8	4	-	-
Mr. Robert McDowell	Director	8	8	3	3
Mr. Gavin Ruddell	Director (FRC Chair)	8	7	3	2
Mr. Tristram Peters	Director (FMC Chair)	8	6	-	-
Ms. Lea-Ann O’Neill	Director	3	2	-	-
Mrs. Kim McNab	Director	8	8	-	-

6. Directors’ Details

The following persons were Directors of Muscular Dystrophy Queensland during 2023. All Directorships are provided in an honorary capacity.

Mr. Victor Attwood
Director: Nov 2017 - Present. (Director under prior structure - Muscular Dystrophy Assoc. of Qld Inc.: 2016 - 2017.)
Special Responsibilities: Board Chair: Nov 2017 - Present. Finance & Risk Committee: 2018 - Present. Nominated Muscular Dystrophy Foundation Australia Ltd Director: 2017 to current.
Skills & Experience: Victor brings extensive management, leadership and governance experience. Victor had a long career in local government, serving as Deputy Mayor of Ipswich City Council and as a senior member of several not-for-profit boards. Victor and his son live with Charcot Marie Tooth, a neuromuscular condition.

Mr. Anthony Biggar LLB
Director: Nov 2017 - Present. (Director under prior structure - Muscular Dystrophy Assoc. of Qld Inc.: 2016 - 2017.)
Special Responsibilities: Nil
Skills & Experience: Tony is the founding Legal Practitioner of Big Law Pty Ltd Solicitors and now practices independently. He is a member of the Property Law and Practice Committees of the Queensland Society and is the Honorary Solicitor for several community organisations in Monto, Queensland.

Dr. Cullen O’Gorman BSc (Hons) MBBS PhD FRACP AFRACMA

Director: Nov 2017 - Present.

Special Responsibilities: Nil

Skills & Experience: Cullen is a specialist Neurologist, Clinical Neurophysiologist and is the Head of Neurology at Brisbane’s Mater hospital. He also consults at the Princess Alexandra hospital and is in private practice. Cullen completed his undergraduate studies in the UK and Australia and postgraduate fellowships at the Mayo Clinic, Rochester, USA.

Mr. Robert McDowell B.Pharm

Director: Sept 2019 - Present.

Special Responsibilities: Nil

Skills & Experience: Bob is a retired pharmacist and was a pharmacy owner for over 30 years. He is a member of the Pharmacy Guild of Australia and served on the Qld branch committee for 12 years, including holding the positions of Vice President Finance and member of the Local Advisory Committee of Pharmaceutical Defence Ltd (PLD). Bob lives with Fascio Scapular Humeral MD (FSHD) and serves on a research committee with FSHD Global.

Mr. Gavin Ruddell B.Com CA RCA

Director: March 2020 - Present.

Special Responsibilities: Chair, Finance & Risk Committee: March 20 - Present.

Skills & Experience: Gavin is a Chartered Accountant, Registered Company Auditor and a Director of Nexia Brisbane Audit with almost two decades of experience in public practice and commercial finance roles. As well as his financial skills set, he brings to the board considerable expertise in corporate governance and risk management.

Mr. Tristram Peters BA BJ MA

Director: March 2021 - Present.

Special Responsibilities: Chair, Fundraising & Marketing Committee: December 2021 - Present.

Skills & Experience: Tristram is Head of Community Engagement with an online disability service directory. He has represented Queensland and Australia playing powerchair football and sits on the board of the Queensland Powerchair Football Association (QPFA), Australian Powerchair Football Association (APFA), and Asia Pacific Oceania (APO) executive committees, helping steer powerchair football’s development. Tristram also co-hosts podcast *Grow Bold with Disability*, exploring with guests stories rarely told about living with disability.

Ms. Lea-Ann McNeill BAppSc BAdult&VocationalEd MLearning&Innov

Director: May 2022 - June 2023

Special Responsibilities: Nil

Skills & Experience: Lea-Ann is the Australia/NZ General Manager for a technology company and has held previous executive roles in Brisbane City Council and the Queensland Police Service. Lea-Ann is also a leader in the Harley Owners’ Group (HOG) and has been on the organising committee of the club’s annual Muscular Dystrophy Charity Ride for many years.

Mrs. Kim McNab BAppSc(EnvHealth)

Director: June 2022 - Present.


Special Responsibilities: Board Rep, Community Liaison Committee

Skills & Experience: Kim has experience in environmental health, health promotion and disability, working in government and the not-for-profit sector. For seven years until 2019, Kim was employed as MDQ’s program coordinator and was influential in the development of services aligned to the NDIS. During this time, working closely with Muscular Dystrophy Foundation Aust., Kim also led the development of the national online resource, TheLoopCommunity.

The Directors’ Report is duly signed for and on behalf of the Directors on the 28th day of March 2024.

Victor Attwood, Chair

Tristram Peters, Director



Muscular Dystrophy Queensland Pty Ltd

ABN: 14 908 553 738

**Financial Statements for the year
ended 31st December, 2023**

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Contents

For the Year Ended 31 December 2023

Page

Financial Statements

Auditor's Independence Declaration under Section 60-40 of the Australian Charities and Not-for-profits Commission Act 2012	1
Statement of Profit or Loss and Other Comprehensive Income	2
Statement of Financial Position	3
Statement of Changes in Equity	4
Statement of Cash Flows	5
Notes to the Financial Statements	6
Directors' Declaration	19
Independent Audit Report	20

Muscular Dystrophy Queensland Ltd


ABN 14 908 553 738

Auditor's Independence Declaration under Section 60-40 of the Australian Charities and Not-for-profits Commission Act 2012 to the Directors of Muscular Dystrophy Queensland Ltd

I declare that, to the best of my knowledge and belief, during the year ended 31 December 2023, there have been:

- (i) no contraventions of the auditor independence requirements as set out in section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Bernard Whebell CA



Ulton Chartered Accountants
20 Main Street, Hervey Bay, Queensland 4655

Dated this 22nd day of March 2024

Brisbane

(07) 3071 3000
Level 3, 89 McLachlan Street
Fortitude Valley Qld 4006

Bundaberg

(07) 4154 0400
62 Woondooma Street
Bundaberg Qld 4670

Fraser Coast

(07) 4197 6300
20 Main Street
Pialba Qld 4655

Gladstone

(07) 4970 6200
Unit 2, 165 Auckland Street
Gladstone Qld 4680

1

info@ulton.net
ulton.net

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Statement of Profit or Loss and Other Comprehensive Income For the Year Ended 31 December 2023

		2023	2022
	Note	\$	\$
Revenue and other income	4.	2,569,012	2,656,076
Fundraising expenses		(300,338)	(310,232)
Client services expenses		(1,123,759)	(1,124,506)
Capital expenses		(70,935)	(130,917)
Operating expenses		<u>(1,115,647)</u>	<u>(1,021,518)</u>
Surplus/(Deficit) before income tax	5.	(41,667)	68,903
Income tax expense		-	-
Surplus/(Deficit) for the year attributable to members		<u>(41,667)</u>	<u>68,903</u>
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year attributable to members		<u>(41,667)</u>	<u>68,903</u>

The accompanying notes form part of these financial statements.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Statement of Financial Position

As At 31 December 2023

	Note	2023 \$	2022 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	6	1,134,886	1,222,870
Trade and other receivables	7	39,488	27,812
Inventories	8	18,082	20,970
Other assets	10	21,877	21,824
TOTAL CURRENT ASSETS		1,214,333	1,293,476
NON-CURRENT ASSETS			
Plant and equipment	9	153,635	136,068
Right-of-use assets	11	90,965	15,950
TOTAL NON-CURRENT ASSETS		244,600	152,018
TOTAL ASSETS		1,458,933	1,445,494
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	12	152,709	168,502
Lease liabilities	11	49,101	8,575
Short-term provisions	13	-	1,149
Employee benefits	15	186,120	174,789
Other liabilities	14	84,923	67,270
TOTAL CURRENT LIABILITIES		472,853	420,285
NON-CURRENT LIABILITIES			
Lease liabilities	11	42,769	7,800
Employee benefits	15	2,150	34,581
TOTAL NON-CURRENT LIABILITIES		44,919	42,381
TOTAL LIABILITIES		517,772	462,666
NET ASSETS		941,161	982,828
EQUITY			
Retained earnings		941,161	982,828
TOTAL EQUITY		941,161	982,828

The accompanying notes form part of these financial statements.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Statement of Changes in Equity For the Year Ended 31 December 2023

2023

	Retained Earnings	Total
	\$	\$
Balance at 1 January 2023	982,828	982,828
Deficit attributable to members	(41,667)	(41,667)
Balance at 31 December 2023	941,161	941,161

2022

	Retained Earnings	Total
	\$	\$
Balance at 1 January 2022	913,925	913,925
Surplus attributable to members	68,903	68,903
Balance at 31 December 2022	982,828	982,828

The accompanying notes form part of these financial statements.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Statement of Cash Flows For the Year Ended 31 December 2023

	2023	2022
Note	\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES:		
Receipts from grants and customers	2,524,292	2,621,588
Payments to suppliers and employees	(2,547,971)	(2,475,364)
Interest received	24,184	6,835
Interest paid on lease	(1,683)	(3,102)
Net cash provided by/(used in) operating activities	18 <u>(1,178)</u>	<u>149,957</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payment for the acquisition of plant and equipment	<u>(67,073)</u>	<u>(47,221)</u>
Net cash provided by/(used in) investing activities	<u>(67,073)</u>	<u>(47,221)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of finance lease liability principal	<u>(19,733)</u>	<u>(84,522)</u>
Net cash provided by/(used in) financing activities	<u>(19,733)</u>	<u>(84,522)</u>
Net increase/(decrease) in cash and cash equivalents held	(87,984)	18,214
Cash and cash equivalents at beginning of year	<u>1,222,870</u>	<u>1,204,656</u>
Cash and cash equivalents at end of financial year	6 <u><u>1,134,886</u></u>	<u><u>1,222,870</u></u>

The accompanying notes form part of these financial statements.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

The financial report covers Muscular Dystrophy Queensland Ltd as an individual entity. Muscular Dystrophy Queensland Ltd is a not-for-profit Company, registered and domiciled in Australia.

The functional and presentation currency of Muscular Dystrophy Queensland Ltd is Australian dollars.

Comparatives are consistent with prior years, unless otherwise stated.

1. Basis of Preparation

In the opinion of the Directors the Company is not a reporting entity since there are unlikely to exist users of the financial statements who are not able to command the preparation of reports tailored so as to satisfy specifically all of their information needs. These special purpose financial statements have been prepared to meet the reporting requirements of the *Australian Charities and Not-for-profits Commission Act 2012*.

The financial statements have been prepared in accordance with the recognition and measurement requirements of the Australian Accounting Standards and Accounting Interpretations, and the disclosure requirements of AASB 101 *Presentation of Financial Statements*, AASB 107 *Statement of Cash Flows*, AASB 108 *Accounting Policies, Changes in Accounting Estimates and Errors* and AASB 1054 *Australian Additional Disclosures*.

The financial statements have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

Significant accounting policies adopted in the preparation of these financial statements are presented below and are consistent with prior reporting periods unless otherwise stated.

2. Summary of Significant Accounting Policies

2.1. Revenue recognition

Grants, donations, bequests and contributions

Where grant, donations, bequests and contribution income from an agreement which is enforceable and contains sufficiently specific performance obligations, then the revenue is recognised when control of each performance obligation is satisfied. Each performance obligation is considered to ensure that the revenue recognition reflects the transfer of control. Revenue is recognised by applying a five-step model as follows:

- Identify the contract with the customer
- Identify the performance obligations
- Determine the transaction price
- Allocate the transaction price
- Recognise revenue

Generally, the timing of the rendering of services corresponds closely to the timing of satisfaction of the performance obligations, however where there is a difference, it will result in the recognition of a receivable, contract asset liability (e.g. unspent grants). Revenue is then recognised as and when it satisfies its performance obligations.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

2. Summary of Significant Accounting Policies

2.1. Revenue recognition

Grants, donations, bequests and contributions

Where the contract is not enforceable or does not have sufficiently specific performance obligations, the Company either recognises the asset received in accordance with the recognition requirements of other applicable accounting standards or recognises income immediately in profit or loss.

Art unions

Revenue primarily comprises of funds raised from the sale of lottery tickets. Revenue is recognised when the Company gains control, economic benefits are probable, and the amount of the contribution can be measured reliably.

Fees from services

Revenue is recognised in accordance with the specific performance obligations of respective contracts with customers. Typically, the customer consumes and receives the benefit of the service as it is provided, therefore revenue is recognised over time as the services are provided.

Interest income

Interest income is recognised using the effective interest method.

All revenue is stated net of the amount of goods and services tax.

2.2. Income tax

The Company is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.

2.3. Goods and services tax (GST)

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of GST.

Cash flows in the statement of cash flows are included on a gross basis and the GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

2.4. Inventories

Inventories are measured at the lower of cost or net realisable value.

2.5. Plant and equipment

Each class of plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

2. Summary of Significant Accounting Policies

2.5. Plant and equipment

Depreciation

Plant and equipment is depreciated on a straight-line basis over the asset's useful life to the Company, commencing when the asset is ready for use.

The depreciation rates used for each class of depreciable asset are shown below:

Fixed asset class	Depreciation rate
Medical equipment	20 - 25%
Furniture, Fixtures and Fittings	16.67 - 20%
Motor Vehicles	16.67 - 20%
Computer Equipment	14.29 - 33.34%

At the end of each annual reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate.

2.6. Financial instruments

Financial instruments are recognised initially using trade date accounting, i.e. on the date that the Company becomes party to the contractual provisions of the instrument. On initial recognition, all financial instruments are measured at fair value plus transaction costs (except for instruments measured at fair value through profit or loss where transaction costs are expensed as incurred).

Financial assets

The Company's financial assets are classified as loans and receivables.

Financial assets are assigned to the different categories on initial recognition, depending on the characteristics of the instrument and its purpose. A financial instrument's category is relevant to the way it is measured and whether any resulting income and expenses are recognised in profit or loss or in other comprehensive income.

All income and expenses relating to financial assets are recognised in the statement of profit or loss and other comprehensive income in the 'finance income' or 'finance costs' line item respectively.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers but also incorporate other types of contractual monetary assets.

After initial recognition these are measured at amortised cost using the effective interest method, less provision for impairment. Any change in their value is recognised in profit or loss.

The Company's trade receivables fall into the category of financial instruments. Receivables expected to be collected in 12 months from the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets.

Notes to the Financial Statements

For the Year Ended 31 December 2023

2. Summary of Significant Accounting Policies

2.6. Financial instruments

Financial assets

In some circumstances, the Company renegotiates repayment terms with customers which may lead to changes in the timing of the payments. The Company does not necessarily consider the balance to be impaired, however assessment is made on a case-by-case basis.

Financial liabilities

The Company's financial liabilities include trade and other payables, which are measured at amortised cost using the effective interest rate method. The effective interest rate method is a method of calculating the amortised cost of a debt instrument and of allocating interest expense in the profit or loss over the relevant period.

Accounts payable and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Company during the reporting period that remains unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

2.7. Impairment of non-financial assets

At the end of each reporting period the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs of disposal and the value in use, is compared to the assets carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss.

Where the future economic benefits of the asset are not primarily dependent upon the asset's ability to generate net cash inflows and when the Company would if deprived of the asset, replace its remaining future economic benefits, value in use is determined as the depreciated replacement cost of the asset.

2.8. Intangible assets

Software

Software is recorded at cost, it has a finite life and is carried at cost less accumulated amortisation and any impairment losses. Software has an estimated useful life of between 1 and 3 years and is assessed annually for impairment.

2.9. Cash and cash equivalents

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

2.10. Leases

At inception of a contract, the Company assesses whether a lease exists i.e. does the contract convey the right to control the use of an identified asset for a period of time in exchange for consideration.

The non-lease components included in the lease agreement have been separated and are recognised as an expense as incurred.

Notes to the Financial Statements

For the Year Ended 31 December 2023

2. Summary of Significant Accounting Policies

2.10. Leases

At the lease commencement, the Company recognises a right-of-use asset and associated lease liability for the lease term. The lease term includes extension periods where the Company believes it is reasonably certain that the option will be exercised.

The right-of-use asset is measured using the cost model where cost on initial recognition comprises of the lease liability, initial direct costs, prepaid lease payments, estimated cost of removal and restoration less any lease incentives received.

The right-of-use asset is depreciated over the lease term on a straight line basis and assessed for impairment in accordance with the impairment of assets accounting policy.

The lease liability is initially measured at the present value of the remaining lease payments at the commencement of the lease. The discount rate is the rate implicit in the lease, however where this cannot be readily determined then the Company's incremental borrowing rate is used.

Subsequent to initial recognition, the lease liability is measured at amortised cost using the effective interest rate method. The lease liability is remeasured whether there is a lease modification, change in estimate of the lease term or index upon which the lease payments are based (e.g. CPI) or a change in the Company's assessment of lease term.

Where the lease liability is remeasured, the right-of-use asset is adjusted to reflect the remeasurement or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

Exceptions to lease accounting

The Company has elected to apply the exceptions to lease accounting for both short-term leases (i.e. leases with a term of less than or equal to 12 months) and leases of low-value assets. The Company recognises the payments associated with these leases as an expense on a straight-line basis over the lease term.

2.11. Employee benefits

Provision is made for the Company's liability for employee benefits, those benefits that are expected to be wholly settled within one year have been measured at the current value of the amounts expected to be paid when the liability is settled.

Changes in the measurement of the liability are recognised in profit or loss.

Defined contribution schemes

Obligations for contributions to defined contribution superannuation plans are recognised as an employee benefit expense in profit or loss in the periods in which services are provided by employees.

2.12. Provisions

Provisions are recognised when the Company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

Provisions are measured at the present value of management's best estimate of the outflow required to settle the obligation at the end of the reporting period. The discount rate used is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

2. Summary of Significant Accounting Policies

2.12. Provisions

provision due to the unwinding of the discount is taken to finance costs in the statement of profit or loss and other comprehensive income.

2.13. New accounting standards and interpretations issued but not yet effective

There are no new Accounting Standards or Interpretations applicable to the Company for application in future periods.

3. Critical Accounting Estimates and Judgements

The Directors make estimates and judgements during the preparation of these financial statements regarding assumptions about current and future events affecting transactions and balances.

These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates.

The significant estimates and judgements made have been described below.

Key estimates

Useful lives of plant and equipment

As described in note 2.5, the Company reviews the estimated useful life of plant and equipment at the end of each reporting period.

Receivables

The receivables at reporting date have been reviewed to determine whether there is any objective evidence that any of the receivables are impaired. An impairment provision is included for any receivable where the entire balance is not considered collectible. The impairment provision is based on the best information at the reporting date.

Key judgements

Performance obligations under AASB 15 Revenue from Contracts with Customers

To identify a performance obligation under AASB 15, the promise must be sufficiently specific to be able to determine when the obligation is satisfied. Management exercises judgement to determine whether the promise is sufficiently specific by taking into account any conditions specified in the arrangement, explicit or implicit, regarding the promised goods or services. In making this assessment, management includes the nature/type, cost/value, quantity and the period of transfer related to the goods or services promised.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

3. Critical Accounting Estimates and Judgements

Lease term and Option to Extend under AASB 16 Leases

The lease term is defined as the non-cancellable period of a lease together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise the option; and also periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. The options that are reasonably going to be exercised is a key management judgement that the Company will make. The Company determines the likelihood to exercise the options on a lease-by-lease basis looking at various factors such as which assets are strategic and which are key to future strategy of the Company. The Company has not included the options to extend the leases in the calculation of its right-to-use assets and lease liabilities.

Employee benefits

For the purpose of measurement, AASB 119 Employee Benefits defines obligations for short-term employee benefits as obligations expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the related service. The Company expects most employees will take their annual leave entitlements within 12 months of the reporting period in which they were earned, but this will not have a material impact on the amounts recognised in respect of obligations for employees' leave entitlements.

4. Other Revenue and Income

	2023	2022
	\$	\$
Fundraising revenue		
- Art unions	82,907	85,118
- Bequests	76,950	69,921
- Charitable grants and contributions	103,908	28,590
- Donations	355,002	393,081
- Events	367,354	387,435
- Total Fundraising revenue	986,121	964,145
- Client service revenue		
- Fees from services	1,416,201	1,246,606
- Government funding	141,397	437,290
- Total Client service revenue	1,557,598	1,683,896
- Operating revenue		
- Earnings on investments	24,184	6,835
- Membership	1,109	1,200
- Total Operating revenue	25,293	8,035
	2,569,012	2,656,076

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

5. Surplus/(Deficit) for the Year

The surplus/(deficit) for the year has been determined after the following specific items:

	2023	2022
	\$	\$
(a) Remuneration of the auditor:		
Auditing the financial report	<u>10,250</u>	10,000
(b) Total employee benefits expenses is comprised of:		
Salaries and wages	1,695,357	1,774,463
Superannuation	<u>184,939</u>	175,669
	<u>1,880,296</u>	1,950,132
(c) Finance costs is comprised of:		
Interest expense on lease liabilities	11. <u>1,683</u>	3,102
(d) Depreciation and amortisation expense is comprised of:		
Depreciation on plant and equipment	9. 46,388	40,811
Depreciation on right-of-use assets	11. <u>20,213</u>	86,334
	<u>66,601</u>	127,145

6. Cash and Cash Equivalents

	2023	2022
	\$	\$
Cash at bank and in hand	<u>1,134,886</u>	1,222,870

7. Trade and Other Receivables

	2023	2022
	\$	\$
CURRENT		
Trade receivables	33,530	27,384
Other receivables	<u>5,958</u>	428
Total current trade and other receivables	<u>39,488</u>	27,812

The carrying value of trade receivables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

The maximum exposure to credit risk at the reporting date is the fair value of each class of receivable in the financial statements.

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

8. Inventories

	2023	2022
	\$	\$
CURRENT		
Merchandise on hand at cost	<u>18,082</u>	<u>20,970</u>

Write downs of inventories to net realisable value during the year were \$ NIL (2022: \$ NIL).

9. Property, Plant and Equipment

PLANT AND EQUIPMENT

Equipment

At cost	76,901	89,098
Accumulated depreciation	<u>(55,821)</u>	<u>(58,758)</u>
Total furniture, fixtures and fittings	<u>21,080</u>	<u>30,340</u>

Motor vehicles

At cost	104,605	104,605
Accumulated depreciation	<u>(55,007)</u>	<u>(39,746)</u>
Total motor vehicles	<u>49,598</u>	<u>64,859</u>

Computer equipment and software

At cost	208,309	142,994
Accumulated depreciation	<u>(125,352)</u>	<u>(102,125)</u>
Total computer software	<u>82,957</u>	<u>40,869</u>

Total plant and equipment

	<u>153,635</u>	<u>136,068</u>
--	----------------	----------------

10. Other Assets

	2023	2022
	\$	\$
CURRENT		
Prepayments	<u>21,877</u>	<u>21,824</u>

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

11. Right-of-use assets

The Company has leases over equipment and buildings. Information relating to the leases in place and associated balances and transactions are provided below.

Terms and conditions of leases

The Company has a lease for its principal place of business, 2996 Logan Road, Underwood. The lease is for an initial term of 2 years expiring in September 2025. The lease has an option to extend for 2 x 3 year periods. The Company has not included the extension option in determining the value of its right-of-use assets as it has not been determined whether it will invoke the option. The lease is subject to a CPI review at each anniversary date.

The Company has two equipment leases for a fixed 5-year term, they do not contain options to extend or any annual review terms.

The Company has elected to measure the right of use asset arising from the concessionary leases at cost which is based on the associated lease liability.

	Buildings	Plant and Equipment	Total
	\$	\$	\$
Year ended 31 December 2023			
Balance at beginning of year	2,538	13,412	15,950
Depreciation charge	(14,442)	(5,771)	(20,213)
Additions to right-of-use assets	95,228	-	95,228
Balance at end of year	83,324	7,641	90,965

	Buildings	Plant and Equipment	Total
	\$	\$	\$
Year ended 31 December 2022			
Balance at beginning of year	83,101	19,183	102,284
Depreciation charge	(80,563)	(5,771)	(86,334)
Balance at end of year	2,538	13,412	15,950

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

11. Right-of-use assets Lease liabilities

The maturity analysis of lease liabilities based on contractual undiscounted cash flows is shown in the table below:

	< 1 year	1 - 5 years	> 5 years	Lease liabilities included in this Statement Of Financial Position
	\$	\$	\$	\$
2023				
Lease liabilities	53,975	44,188	-	91,870
2022				
Lease liabilities	8,575	7,800	-	16,375

	2023	2022
	\$	\$
Interest expense on leases reported in the Statement of Profit or Loss	1,683	3,102
Total cash outflows for leases in the Statement of Cash Flows	50,212	87,625

12. Trade payables and accrued expenses

	2023	2022
	\$	\$
CURRENT		
Trade and other payables	152,709	168,502

Trade and other payables are unsecured, non-interest bearing and are normally settled within 30 days. The carrying value of trade and other payables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

13. Provisions

	2023	2022
	\$	\$
CURRENT		
Make good provision	-	1,149

14. Other Liabilities

	2023	2022
CURRENT		
Unearned revenue	84,923	67,270

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

15. Employee Benefits

	2023	2022
	\$	\$
Current liabilities		
Provision for long service leave	56,002	50,282
Provision for annual leave	130,118	124,507
	186,120	174,789
Non-current liabilities		
Provision for long service leave	2,150	34,581

16. Members' Guarantee

The Company is registered with the *Australian Charities and Not-for-profits Commission* and is a Company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$ 10 each towards meeting any outstanding obligations of the Company. At 31 December 2023 the number of members was 16 (2022: 35).

17. Contingencies

In the opinion of those charged with governance, the Company did not have any contingencies at 31 December 2023 (31 December 2022:None).

18. Cash Flow Information

The following is the reconciliation of the result for the year to cash flows from operating activities:

	2023	2022
	\$	\$
Surplus/(deficit) for the year	(41,667)	68,903
Cash flows excluded from profit attributable to operating activities		
Non-cash flows in profit:		
- depreciation - plant and equipment	46,388	40,811
- depreciation - right of use assets	20,213	86,334
- impairment of non-current other asset	-	11,424
- net loss on disposal of property, plant and equipment	3,118	-
Changes in assets and liabilities:		
- (increase)/decrease in trade and other receivables	(11,676)	(21,430)
- (increase)/decrease in other assets	(53)	(6,222)
- (increase)/decrease in inventories	2,888	2,858
- increase/(decrease) in trade and other payables	(15,793)	(42,235)
- (increase)/decrease in other liabilities	17,653	(37,190)
- increase/(decrease) in employee benefits and other provisions	(22,249)	46,704
Cashflows from operations	(1,178)	149,957

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Notes to the Financial Statements For the Year Ended 31 December 2023

19. Events Occurring After the Reporting Date

The financial report was authorised for issue on 28th March 2024 by the board of directors.

There have been no matters or circumstances since the end of the financial year which specifically affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in the future financial years.

20. Statutory Information

The registered office and principal place of business of the Company is:

Muscular Dystrophy Queensland Ltd
2996 Logan Road
Underwood QLD 4119

Muscular Dystrophy Queensland Ltd

ABN 14 908 553 738

Directors' Declaration

In accordance with a resolution of the Directors of Muscular Dystrophy Queensland Ltd, the Directors of the Registered Entity declare that, in the Directors' opinion:

1. The financial statements and notes, as set out on pages 2 to 18, Satisfy the requirements of the *Australian Charities and Not-for-profits Commission Act 2012* and:
 - (a) Comply with Australian Accounting Standards applicable to the Registered Entity to the extent described in Note 1.; and
 - (b) Give a true and fair view of the financial position of the Registered Entity as at 31 December 2023 and of its performance for the year ended on that date.
2. There are reasonable grounds to believe that the Registered Entity will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with the subs 60.15(2) of the *Australian Charities and Not-for-profit Commission Regulation 2022*.

Director
Victor Attwood

Director
Gavin Ruddell

Dated thistwenty-eighth..... day ofMarch..... 2024

Muscular Dystrophy Queensland Ltd

Independent Audit Report to the members of Muscular Dystrophy Queensland Ltd

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Muscular Dystrophy Queensland Ltd, which comprises the statement of financial position as at 31 December 2023, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion the financial report of Muscular Dystrophy Queensland Ltd has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) giving a true and fair view of the Registered Entity's financial position as at 31 December 2023 and of its financial performance for the year ended; and
- (ii) complying with Australian Accounting Standards to the extent described in Note 1., and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Registered Entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter - Basis of Accounting

We draw attention to Note 1. to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Registered Entity's financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of Responsible Entities for the Financial Report

The responsible persons of the Registered Entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1. to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The responsible entities' responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Muscular Dystrophy Queensland Ltd

Independent Audit Report to the members of Muscular Dystrophy Queensland Ltd

In preparing the financial report, the responsible persons are responsible for assessing the Registered Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intend to liquidate the Registered Entity or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.



Bernard Whebell CA

20 Main Street, Hervey Bay Queensland 4655

Dated this 10th day of April 2024



We're stronger **together**

1159 Sandgate Rd, Nundah Qld 4012 | Locked Bag 3000, Eagle Farm BC, Qld, 4009
t: 07 3243 9700 e: info@mdqld.org.au w: mdqld.org.au

Published May 2023